Consilience Ventures
VC Fund
London, United Kingdom
Consilience Ventures is an innovative, data-driven investment community built solely to encourage and stimulate rapid growth for early stage start-ups. It’s a new way of getting start-ups off the ground, more reliably, more profitably, and at a lower cost to both founders and investors.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Consilience Ventures invests in
Stages Consilience Ventures invests in
Countries Consilience Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $1M–$1.9M
Investment Focus
Industry
- Health Care 3 (43%)
- Medical 2 (29%)
- Software 2 (29%)
- Machine Learning 2 (29%)
- Artificial Intelligence 2 (29%)
Stage
- Seed 4 (57%)
- Venture - Series Unknown 2 (29%)
- Pre-Seed 1 (14%)
Country
- United Kingdom 4 (57%)
- Ireland 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Kevin Monserrat
CEO & Founder
|
CEO & Founder | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cerebreon Technologies
|
Cerebreon Technologies specializes in advanced data analytics, business management systems and process automation. Cerebreon Technologies Ltd. provides bespoke software solutions and expert consultancy services to enterprises with a mission to make high-end analytics accessible to all businesses, irrespective of their size or sector. | Venture - Series Unknown / Jan 01, 2022 | |
QV Bioelectronics
|
Time is precious and for patients with the most common brain tumour, glioblastoma, the value of that time really comes into focus when they are suddenly hit with the news there is no cure and that they have just one year to live. Current treatment options are not good enough and come at a huge cost to the quality of that remaining time. Ourco-founder Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for his brain tumour patients but also by major design flaws in newer electrotherapy approaches. Working together with Dr Chris Bullock, a biomedical engineer arising from Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. Together they formed QV Bioelectronics, and since then, their ground-breaking research has received over $425k in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK. The technology core patent has been filed, with full FTO. Additionally, alongside Dr Fu's expertise, the clinical advisory board contains some of Britain's top neurosurgeons who are helping to input into the feedback of the technology design. Our aim is to double patient life expectancy compared to standard treatment without impacting quality of life, so patients can focus on what matters. Join us at QV Bioelectronics, in pioneering a better option for terminal cancer patients. | $1M / Seed / Jun 30, 2021 | |
Checkstep
|
CheckStep provides a AI-powered Trust & Safety and UGC management software to online platform worldwide. It enables company to manage the full policy management life-cycle. | $430K / Pre-Seed / Jun 28, 2021 | |
|
Checkstep
|
CheckStep provides a AI-powered Trust & Safety and UGC management software to online platform worldwide. It enables company to manage the full policy management life-cycle. | $1.8M / Seed / Jun 28, 2021 | |
Jiva.ai
|
Jiva is a UK-based AI company that will change the way we all build machine learning models.The core technology puts fusion at the heart of its learning procedure, enabling multimodal AI. Fusion is the process by which one can iteratively build partial models independently and then join them together to create bigger and better representations.Model fusion is a fundamental prerequisite to artificial general intelligence. Using the platform as a basis, the Jiva team will build practical diagnostic solutions to human diseases.Jiva builds use-cases in specific disease areas as well having a platform for data scientists to build their models. Jiva has created solutions for prostate cancer MRI analysis to identify clinically relevant tumours, liver disease diagnosis as well as bone fracture identification. | $1.8M / Seed / May 27, 2021 | |
SIME
|
SIME is a clinical AI platform company committed to preventative, personalized point-of-care medicine. Their solutions provide data-driven and precise insights to doctors in decisive moments, when rapid intervention can save a life. Developed by world-renowned scientists and doctors, their data engine detects disease in real-time, enabling earlytreatment in high-risk patients. The first urgent unmet needs that we are addressing are in the neonatal intensive care unit; where our clinically proven, and patented technologies will have the greatest impact. Through curation and analysis, their AI platform generates unique datasets which can be used by SIME to discover new products, or by third-party commercial partners in all areas of medicine. SIME is a London (UK), Copenhagen (Denmark), and Shanghai (China) based company with over three decades of experience of pioneering innovation in medicine and data science. | Venture - Series Unknown / Jan 01, 2021 | |
|
Cerebreon Technologies
|
Cerebreon Technologies specializes in advanced data analytics, business management systems and process automation. Cerebreon Technologies Ltd. provides bespoke software solutions and expert consultancy services to enterprises with a mission to make high-end analytics accessible to all businesses, irrespective of their size or sector. | $1.9M / Seed / Apr 01, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Consilience Ventures invest in?
Consilience Ventures invests primarily in Health Care, Medical and Software startups, most often at Seed and Venture - Series Unknown stage. Most of the 7 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Consilience Ventures's check size?
Consilience Ventures typically joins rounds of $1M–$1.9M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Consilience Ventures participates in.
How do I contact Consilience Ventures?
Public channels for Consilience Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Consilience Ventures?
The team at Consilience Ventures includes Kevin Monserrat (CEO & Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
